Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) For An Interferon-Free Regimen Of Sofosbuvir (GS-7977), GS-5885 And Ribavirin In Treatment-Naïve Genotype 1 Hepatitis C Infected Patients
Gilead Sciences (Nasdaq: GILD) today announced interim data from the
ongoing Phase 2 ELECTRON study examining a 12-week course of therapy
with the investigational nucleotide sofosbuvir (formerly referred to as
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.